|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
|
DE69633947T2
(de)
*
|
1995-12-08 |
2005-12-01 |
Agouron Pharmaceuticals, Inc., San Diego |
Zwischenprodukte zur Herstellung von Metallproteinasehemmern
|
|
US6747027B1
(en)
*
|
1996-07-22 |
2004-06-08 |
Pharmacia Corporation |
Thiol sulfonamide metalloprotease inhibitors
|
|
KR20000068414A
(ko)
*
|
1996-09-04 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도
|
|
US6624177B1
(en)
|
1996-09-04 |
2003-09-23 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
|
CA2256631A1
(en)
|
1996-09-04 |
1998-03-12 |
Warner-Lambert Company |
Compounds for and a method of inhibiting matrix metalloproteinases
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
EP1028716A1
(en)
*
|
1996-12-09 |
2000-08-23 |
Warner-Lambert Company |
Method for treating and preventing heart failure and ventricular dilatation
|
|
AU737117B2
(en)
*
|
1996-12-17 |
2001-08-09 |
Warner-Lambert Company |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
|
|
EP1366765A1
(en)
*
|
1996-12-17 |
2003-12-03 |
Warner-Lambert Company Llc |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
|
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
US6432994B1
(en)
|
1997-04-28 |
2002-08-13 |
Texas Biotechnology Corporation |
Sulfonamides for treatment of endothelin-mediated disorders
|
|
PT877019E
(pt)
|
1997-05-09 |
2002-05-31 |
Hoechst Ag |
Acidos diaminocarboxilicos substituidos
|
|
DE19719621A1
(de)
*
|
1997-05-09 |
1998-11-12 |
Hoechst Ag |
Sulfonylaminocarbonsäuren
|
|
US6410580B1
(en)
|
1998-02-04 |
2002-06-25 |
Novartis Ag |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
EP1053226A1
(en)
|
1998-02-04 |
2000-11-22 |
Novartis AG |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
WO2000015213A1
(en)
*
|
1998-09-11 |
2000-03-23 |
Shionogi & Co., Ltd. |
Remedal or preventive agent for congestive heart failure
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
US6358980B1
(en)
|
1999-01-27 |
2002-03-19 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6465508B1
(en)
|
2000-02-25 |
2002-10-15 |
Wyeth |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
|
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
|
WO2003037852A1
(en)
|
2001-11-01 |
2003-05-08 |
Wyeth Holdings Corporation |
Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
ES2325205T3
(es)
*
|
2001-12-20 |
2009-08-28 |
Bristol-Myers Squibb Company |
Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
|
|
US6864478B2
(en)
*
|
2002-04-22 |
2005-03-08 |
Visx, Incorporation |
Beam position monitoring for laser eye surgery
|
|
WO2005021489A2
(en)
|
2002-12-23 |
2005-03-10 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
|
US20040225077A1
(en)
|
2002-12-30 |
2004-11-11 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
US7537774B2
(en)
*
|
2005-12-23 |
2009-05-26 |
Orion Therapeautics, Llc |
Therapeutic formulation
|
|
JPWO2007102392A1
(ja)
*
|
2006-03-03 |
2009-07-23 |
塩野義製薬株式会社 |
Ｍｍｐ−１３選択的阻害剤
|
|
JPWO2008053913A1
(ja)
*
|
2006-11-02 |
2010-02-25 |
塩野義製薬株式会社 |
Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
|
|
US8093276B2
(en)
*
|
2007-10-31 |
2012-01-10 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
|
|
US8084477B2
(en)
|
2007-10-31 |
2011-12-27 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
|
|
WO2009137657A1
(en)
*
|
2008-05-08 |
2009-11-12 |
Bristol-Myers Squibb Company |
2-aryl glycinamide derivatives
|
|
US8044077B2
(en)
*
|
2009-03-19 |
2011-10-25 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
|
|
US7977362B2
(en)
*
|
2009-03-20 |
2011-07-12 |
Bristol-Myers Squibb Company |
Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
|
|
US20110071199A1
(en)
*
|
2009-03-20 |
2011-03-24 |
Bristol-Myers Squibb Company |
Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
|
|
TW201043269A
(en)
*
|
2009-04-14 |
2010-12-16 |
Bristol Myers Squibb Co |
Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
|
|
US8252821B2
(en)
*
|
2009-04-14 |
2012-08-28 |
Bristol-Myers Squibb Company |
Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
|